Last reviewed · How we verify
Ferric Citrate 1 GM Oral Tablet [AURYXIA]
Ferric citrate binds phosphate in the gastrointestinal tract to reduce serum phosphate levels in patients with chronic kidney disease.
Ferric citrate binds phosphate in the gastrointestinal tract to reduce serum phosphate levels in patients with chronic kidney disease. Used for Hyperphosphatemia in patients with chronic kidney disease on dialysis, Iron deficiency anemia in patients with chronic kidney disease.
At a glance
| Generic name | Ferric Citrate 1 GM Oral Tablet [AURYXIA] |
|---|---|
| Also known as | Auryxia |
| Sponsor | USRC Kidney Research |
| Drug class | Phosphate binder |
| Target | Dietary phosphate (non-receptor mechanism) |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | Phase 3 |
Mechanism of action
Ferric citrate is an iron-based phosphate binder that forms insoluble complexes with dietary phosphate in the GI lumen, preventing phosphate absorption and reducing serum phosphate concentrations. This mechanism helps manage hyperphosphatemia in chronic kidney disease patients while simultaneously providing supplemental iron, which can help address iron deficiency anemia common in this population.
Approved indications
- Hyperphosphatemia in patients with chronic kidney disease on dialysis
- Iron deficiency anemia in patients with chronic kidney disease
Common side effects
- Diarrhea
- Nausea
- Constipation
- Abdominal discomfort
- Discolored feces
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: